CVSKL has recently achieved a groundbreaking milestone by successfully performing its inaugural MitraClip™ procedure, solidifying its position as one of Malaysia’s pioneering private hospitals to offer this cutting-edge treatment for mitral valve regurgitation.
Dr. Al Fazir, a distinguished consultant cardiologist at CVSKL, underscores the significance of the MitraClip™ procedure, emphasizing its potential to address mitral valve regurgitation without the necessity of open-heart surgery. This innovative approach provides a pivotal opportunity to mitigate valve malfunction.
The heart, a remarkable one-way pump comprising four chambers and four valves, relies on the coordinated movement of these flaps (leaflets or cusps) to ensure a unidirectional blood flow. When the mitral valve’s performance falters due to incomplete sealing or structural alterations, blood leakage—termed mitral valve regurgitation—occurs. This condition, if left untreated, can lead to severe complications such as heart failure and irregular heart rhythms.
What sets the MitraClip™ procedure apart is its non-invasive nature, eliminating the need for traditional mitral valve surgery. This makes it particularly appealing for older individuals, high-risk patients, and those contending with underlying health issues.
Under the leadership of consultant cardiologist Dr. Al Fazir Omar, supported by esteemed cardiologists Dr. Choo Gim Hooi and Datuk Dr. David Chew Soon Ping, the CVSKL team orchestrated the procedure with remarkable success, culminating after approximately four hours. Dr. Al Fazir shares his enthusiasm, noting the procedure’s potential for swifter recovery, exemplified by a two-day post-procedure discharge. “The MitraClip procedure is a game-changer for mitral valve regurgitation treatment,” he adds.
Dr. Choo further underscores the importance of collaborative teamwork in this achievement, acknowledging the synergy between the adept cardiologists and the dedicated surgical team. Dr. David extends his appreciation to the radiographers and nurses in the cathlab, acknowledging their integral role in the success of advanced interventions like MitraClip™.
This landmark achievement amplifies CVSKL’s stature in treating mitral valve regurgitation, reinforcing their Structural Heart Program. The inclusion of MitraClip™ in their repertoire aligns with their aspiration to position CVSKL as a Center of Excellence for comprehensive cardiovascular care.
For further inquiries, interested individuals can reach out during office hours via phone or WhatsApp at +603 2276 7002 or through email at info@cvskl.com.
